Payment overview · 2025
General Payments
$808.78
40 reported records · 24 companies
Healthcare provider profile · identity verified
James E Alonso, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · SAINT LOUIS, MO · NPI 1063506566
Verified facts
What the public records show
CMS Open Payments records show James E Alonso, M.D. received $808.78 in general payments during 2025 across 40 reported records.
ABBVIE INC. accounted for 12.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Fycompa.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Fycompa by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $99.92 | 12.3% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $67.75 | 8.4% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $47.39 | 5.9% | 3 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $47.18 | 5.8% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $47.16 | 5.8% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $44.76 | 5.5% | 2 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$43.54 | 5.4% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $42.05 | 5.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $39.91 | 4.9% | 2 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $34.45 | 4.3% | 2 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $30.74 | 3.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $30.73 | 3.8% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.75 | 3.4% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $23.67 | 2.9% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $22.95 | 2.8% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $22.91 | 2.8% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $20.29 | 2.5% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$19.47 | 2.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18.62 | 2.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.81 | 2.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.44 | 1.9% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.43 | 1.9% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $15.37 | 1.9% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $13.49 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $808.78 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $58.26 | 3 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $47.39 | 3 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $47.18 | 2 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $47.18 | 2 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $47.16 | 2 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $45.13 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $44.76 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $42.05 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $41.66 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $41.10 | 2 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $39.91 | 2 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $34.45 | 2 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $30.74 | 2 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $30.73 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $27.75 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $19.47 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
44 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levetiracetam | Levetiracetam | 226 | 47 |
| Gabapentin | Gabapentin | 164 | 57 |
| Topiramate | Topiramate | 151 | 26 |
| Lamotrigine | Lamotrigine | 117 | 24 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 87 | 26 |
| Pregabalin | Pregabalin | 85 | 18 |
| Divalproex Sodium | Divalproex Sodium | 83 | 11 |
| Donepezil Hcl | Donepezil Hcl | 83 | 21 |
| Memantine Hcl | Memantine Hcl | 68 | 16 |
| Zonisamide | Zonisamide | 63 | 11 |
| Phenobarbital | Phenobarbital | 57 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 52 | 39 |
| Sumatriptan Succinate | Sumatriptan Succinate | 51 | 14 |
| Primidone | Primidone | 47 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | suppressed |
| Eliquis | Apixaban | 44 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 43 | 35 |
| Carbamazepine Er | Carbamazepine | 42 | suppressed |
| Clonazepam | Clonazepam | 42 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 40 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 37 | 34 |
| Oxycodone Hcl | Oxycodone Hcl | 34 | 31 |
| Sertraline Hcl | Sertraline Hcl | 34 | suppressed |
| Lacosamide | Lacosamide | 33 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 31 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 31 | suppressed |
| Carbamazepine | Carbamazepine | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | 11 |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Clobazam | Clobazam | 27 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 25 | 11 |
| Epidiolex | Cannabidiol (Cbd) | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 23 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 22 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 20 | 17 |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 16 |
| Trazodone Hcl | Trazodone Hcl | 19 | 13 |
| Aimovig Autoinjector | Erenumab-Aooe | 18 | suppressed |
| Baclofen | Baclofen | 18 | 12 |
| Carvedilol | Carvedilol | 18 | 18 |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 16 | 16 |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Felbamate | Felbamate | 16 | suppressed |
| Furosemide | Furosemide | 16 | 16 |
| Fycompa | Perampanel | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Prednisone | Prednisone | 16 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 15 | 15 |
| Diazepam | Diazepam | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Losartan Potassium | Losartan Potassium | 14 | 14 |
| Azathioprine | Azathioprine | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | 12 |
| Nourianz | Istradefylline | 13 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 13 | 13 |
| Tramadol Hcl | Tramadol Hcl | 13 | 13 |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | 12 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | 11 |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $808.78 · 40 records | ABBVIE INC. | AUSTEDO XR, CREXONT, Dysport, EMGALITY, FYCOMPA, Gamunex-C, Hizentra, INCEPTIV, INFINITY, INGREZZA, KESIMPTA, KISUNLA, NUPLAZID, NURTEC ODT, Nayzilam, ONPATTRO, Ocrevus Zunovo, QULIPTA, Senza, TYSABRI, UBRELVY, VALTOCO, VUMERITY, VYALEV, VYEPTI, VYVGART HYTRULO, WAINUA, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Fycompa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with CATALYST PHARMACEUTICALS, INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error